Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK3965193 + bepirovirsen
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral (GSK3965193), Subcutaneous (bepirovirsen)
01
Overview
GSK3965193 + bepirovirsen is an investigational combination therapy composed of two agents in clinical development for the treatment of chronic hepatitis B infection. **GSK3965193** is an oral agent with a novel mechanism targeting hepatitis B surface antigen (HBsAg) reduction, though its precise molecular target remains undisclosed. **Bepirovirsen** is an antisense oligonucleotide designed to bind to hepatitis B virus (HBV) messenger RNAs, thereby reducing synthesis of all HBV proteins including HBsAg. The rationale for the combination is to achieve a sustained functional cure of chronic hepatitis B by simultaneously reducing circulating viral proteins and stimulating immune control. Both agents have demonstrated the ability to lower HBsAg: GSK3965193 in preclinical and early clinical studies and bepirovirsen in phase II/III trials. Combination studies are currently in early-phase evaluation to assess safety, tolerability, and preliminary efficacy in people living with chronic hepatitis B, with the goal of achieving higher functional cure rates than monotherapy[1][3][7].
- Other names
- bepirovirsen + GSK3965193
02
Targets
HBV RNA (Hepatitis B virus RNA)
Beyond the preview
Go deeper on GSK3965193 + bepirovirsen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK3965193 + bepirovirsen.